18:23 , Feb 16, 2018 |  BC Week In Review  |  Financial News

Catalyst raises $115M follow-on

Catalyst Biosciences Inc. (NASDAQ:CBIO) raised $115 million through the sale of 3.4 million shares at $34 in a follow-on underwritten by JonesTrading Institutional Services, Ladenburg Thalmann, LifeSci Capital and B. Riley FBR. The figures include...
22:28 , Feb 13, 2018 |  BC Extra  |  Financial News

Catalyst prices $100M follow-on

Catalyst Biosciences Inc. (NASDAQ:CBIO) raised $100 million through the sale of 2.9 million shares at $34 in a follow-on underwritten by JonesTrading Institutional Services, Ladenburg Thalmann, LifeSci Capital and B. Riley FBR. The price is...
19:29 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Hemophilia Cell culture and mouse studies suggest an engineered mutant Factor VIIa/Tissue Factor complex could help treat hemophilia A. The mutant complex consisted of Factor VIIa and soluble TF harboring Q64C and G109C mutations, respectively,...
22:55 , May 19, 2017 |  BioCentury  |  Strategy

Full set in hemophilia

Pfizer Inc.’s deal with Sangamo Therapeutics Inc. brings in what the pharma believes is the last of three mechanisms it needs to cover the hemophilia population with new non-factor replacement therapies. The companies announced the worldwide...
00:26 , Apr 15, 2017 |  BioCentury  |  Product Development

Outside factors

This year could see the first regulatory submission from a coming wave of new therapies for hemophilia prophylaxis that do not simply replace missing clotting factors, which has been the standard for care for decades....
20:51 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

Eptacog beta regulatory update

FDA accepted for review a BLA from LFB for eptacog beta to treat congenital hemophilia A or B in adolescents and adult congenital hemophilia A or B patients with inhibitors. HEMA Biologics LLC (Louisville, Ky.),...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Catalyst Biosciences hematology news

Catalyst will reduce headcount by 10 (50%) to about 10 to focus resources on its hemostasis programs, primarily CB 813d and CB 2679d ( ISU 304). The company said it will continue to...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Company News

Serendex, Savara deal

Savara acquired fellow pulmonary company Serendex in a stock deal. Savara will gain Molgradex, a nebulized form of recombinant human GM-CSF that is in Phase II/III testing to treat autoimmune pulmonary alveolar proteinosis; and...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

IV Factor VIIa-CTP: Phase IIa started

Opko began an open-label, dose-escalation, U.S. Phase IIa trial to evaluate single doses of IV Factor VIIa-CTP in about 24 adult male patients. Later this year, Opko plans to start a Phase IIa trial of...